Marcus Neubauer, MD

COVID-19 has created a significant distraction from normal practice operations. The uncertainty that comes along with the pandemic is a huge worry, and can distract from practice transformation.

As the cost of oncology drugs only continues to rise, incorporating clinical pathways into cancer care helps streamline the integration of evidence-based best practices while improving quality and reducing costs for patients and payers.

The shift to value-based care, concurrent with innovations in immune-based care, will create challenges in oncology. What should be the physician and manufacturer responsibility during these changing times?